Tumor-infiltrating leukocytes suppress local inflammation via interleukin-1 receptor antagonist in a syngeneic prostate cancer model

Yu Ching Fan, Wei Yu Chen, Kuan Der Lee, Yuan Chin Tsai

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)

Abstract

Background: Several lines of evidence have demonstrated the tumor-promoting function of inflammation. Since many chemokines are important in coordinating immune cells during inflammation, monitoring intratumoral chemokines provides a way to study the tumor microenvironment. Methods: To identify tumorigenic chemokines, we compared two syngeneic mouse prostate cancer cell lines by an antibody array and quantitative reverse-transcription polymerase chain reaction (RT-PCR). The tumor microenvironment was analyzed by monitoring gene expressions in mouse tumor tissues, primary cells, and tumor-infiltrating leukocytes (TILs). Result: We identified a group of pro-inflammatory chemokines associated with a tumorigenic transgenic adenocarcinoma mouse prostate (TRAMP)-C1 cell line. In the tumor microenvironment, the TILs secrete a natural anti-inflammatory factor, interleukin-1 receptor antagonist (IL1RN), which inhibits the functions of pro-inflammatory molecules and likely accounts for tumor type-specific anti-inflammation functions. Conclusion: Our results support that tumor cells recruit TILs by pro-inflammatory chemokines to establish an IL1RN-mediated anti-inflammatory environment in the syngeneic prostate cancer model.

Original languageEnglish
Article number67
JournalBiology
Volume9
Issue number4
DOIs
Publication statusPublished - Apr 2020

Keywords

  • Interleukin-1 receptor antagonist
  • Tumor microenvironment
  • Tumor-infiltrating leukocytes

ASJC Scopus subject areas

  • General Biochemistry,Genetics and Molecular Biology
  • General Immunology and Microbiology
  • General Agricultural and Biological Sciences

Fingerprint

Dive into the research topics of 'Tumor-infiltrating leukocytes suppress local inflammation via interleukin-1 receptor antagonist in a syngeneic prostate cancer model'. Together they form a unique fingerprint.

Cite this